GEN Exclusives

More »

GEN News Highlights

More »
Dec 4, 2006

BASF Will Manufacture Astaxanthin for Cardax

  • BASF will exclusively manufacture a specialized form of astaxanthin, a key intermediate used to make Cardax Pharmaceuticals’ lead compound, Xancor™, for cardiovascular inflammatory disease.

    BASF will produce this material in sufficient quantity for preclinical, clinical, and eventually commercial use, according to the joint development and supply agreement between the two companies.

    As part of the agreement, Cardax has granted BASF an option for a royalty-bearing license for nutraceutical use of the specialized form of astaxanthin. All pharmaceutical applications of Xancor will remain the property of Cardax.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?